Notably, in 2012, Tsunemi et al. showed that the ability of PGC-1α to clear mutant Huntingtin was dependent on TFEB, suggesting that PGC-1α and TFEB are potential therapeutic targets for Huntington and other neurodegenerative diseases [31]. The gene discussed is HTT; the disease is neurodegenerative disease.